This company is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Humanigen Crescita futura
Future criteri di controllo 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Humanigen.
Informazioni chiave
n/a
Tasso di crescita degli utili
n/a
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 28.5% |
Tasso di crescita dei ricavi | n/a |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | None |
Ultimo aggiornamento | n/a |
Aggiornamenti recenti sulla crescita futura
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Humanigen non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.
Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.
Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
3/31/2023 | 2 | -54 | -64 | -64 | N/A |
12/31/2022 | 3 | -71 | -77 | -77 | N/A |
9/30/2022 | 3 | -109 | -94 | -94 | N/A |
6/30/2022 | 4 | -152 | -125 | -125 | N/A |
3/31/2022 | 4 | -192 | -168 | -168 | N/A |
12/31/2021 | 4 | -237 | -184 | -184 | N/A |
9/30/2021 | 3 | -235 | -175 | -175 | N/A |
6/30/2021 | 2 | -199 | -151 | -151 | N/A |
3/31/2021 | 1 | -153 | -105 | -105 | N/A |
12/31/2020 | 0 | -90 | -70 | -70 | N/A |
9/30/2020 | N/A | -59 | -47 | -47 | N/A |
6/30/2020 | N/A | -31 | -24 | -24 | N/A |
3/31/2020 | N/A | -10 | -4 | -4 | N/A |
12/31/2019 | N/A | -10 | -4 | -4 | N/A |
9/30/2019 | N/A | -10 | -5 | -5 | N/A |
6/30/2019 | N/A | -10 | -5 | -5 | N/A |
3/31/2019 | N/A | -9 | -5 | -5 | N/A |
12/31/2018 | N/A | -12 | -6 | -6 | N/A |
9/30/2018 | N/A | -13 | -7 | -7 | N/A |
6/30/2018 | N/A | -18 | -10 | -10 | N/A |
3/31/2018 | N/A | -22 | -12 | -12 | N/A |
12/31/2017 | N/A | -22 | -14 | -14 | N/A |
9/30/2017 | N/A | -24 | -15 | -15 | N/A |
6/30/2017 | N/A | -21 | -20 | -20 | N/A |
3/31/2017 | N/A | -27 | -23 | -23 | N/A |
12/31/2016 | N/A | -27 | N/A | -21 | N/A |
9/30/2016 | N/A | -35 | N/A | -26 | N/A |
6/30/2016 | N/A | -37 | N/A | -23 | N/A |
3/31/2016 | N/A | -31 | N/A | -22 | N/A |
12/31/2015 | N/A | -35 | N/A | -29 | N/A |
9/30/2015 | N/A | -32 | N/A | -28 | N/A |
6/30/2015 | N/A | -33 | N/A | -30 | N/A |
3/31/2015 | N/A | -37 | N/A | -34 | N/A |
12/31/2014 | N/A | -38 | N/A | -36 | N/A |
9/30/2014 | 0 | -39 | N/A | -39 | N/A |
6/30/2014 | 0 | -42 | N/A | -39 | N/A |
3/31/2014 | 0 | -44 | N/A | -42 | N/A |
12/31/2013 | 0 | -42 | N/A | -39 | N/A |
9/30/2013 | 0 | -43 | N/A | -37 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Insufficient data to determine if HGEN.Q's forecast earnings growth is above the savings rate (2.4%).
Guadagni vs Mercato: Insufficient data to determine if HGEN.Q's earnings are forecast to grow faster than the US market
Guadagni ad alta crescita: Insufficient data to determine if HGEN.Q's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: Insufficient data to determine if HGEN.Q's revenue is forecast to grow faster than the US market.
Ricavi ad alta crescita: Insufficient data to determine if HGEN.Q's revenue is forecast to grow faster than 20% per year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if HGEN.Q's Return on Equity is forecast to be high in 3 years time